Developer docs
API playgroundTry for free, no card

Search company profiles

abcendo

Full company profile

uuid02m8wz2

Namestring
abcendo
Legal namestring
Adcendo ApS
Websiteurl
adcendo.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Adcendo ApS is a clinical-stage biotechnology company founded in 2017 as a spin-out from the University of Copenhagen and Rigshospitalet, headquartered in Copenhagen, Denmark, with US operations established through Adcendo U.S. Inc. in Boston, Massachusetts in April 2025. The company develops a portfolio of first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need, integrating novel target biology with optimized linker-payload combinations. Adcendo's pipeline consists of three clinical-stage ADC candidates: ADCE-T02, a potential best-in-class Tissue Factor-targeting ADC using a next-generation exatecan-based T1000 linker-payload for solid tumors including HNSCC, PDAC, CRC, NSCLC, and cervical cancer; ADCE-D01, a first-in-class ADC targeting uPARAP (urokinase plasminogen activator receptor-associated protein) conjugated to the P1021 topoisomerase I inhibitor payload for mesenchymal cancers including soft tissue sarcoma, and granted FDA Fast Track and Orphan Drug Designation; and ADCE-B05, a first-in-class ADC against an undisclosed target in squamous cell carcinomas. The company also holds a preclinical discovery asset (A0401) and has licensed the DITAC linker/payload platform from Duality Biologics.

As a pre-revenue clinical-stage company, Adcendo generates no product sales today. Its economic model is structured around licensing, milestone, and royalty agreements with pharmaceutical partners. The principal commercial agreement is a global development and commercialization deal with Multitude Therapeutics for ADCE-T02 (excluding Greater China), which could deliver over $1 billion in upfront and milestone payments plus single-digit to low double-digit tiered royalties. A clinical collaboration with MSD will evaluate ADCE-T02 in combination with KEYTRUDA (pembrolizumab) in a Phase Ib study. Future revenue will ultimately derive from product commercialization through specialty oncology channels following regulatory approval, complemented by licensing income.

The company has raised approximately $453 million across multiple financing rounds including a EUR 98 million Series A (with extensions in 2021, 2023, and 2024), a $135 million Series B in November 2024 led by TCGX, and a $75 million Series C in April 2026 led by Jeito Capital. The investor base comprises a syndicate of healthcare specialist funds including TCGX, Jeito Capital, Novo Holdings, RA Capital, TPG, Orbimed, Pontifax, Ysios, HealthCap, Gilde Healthcare, Venrock, Surveyor Capital (Citadel), Logos Capital, Vida Ventures, BPI France, EIFO, and Dawn Biopharma (KKR platform). Leadership includes CEO Michael Pehl, formerly of Celgene and Immunomedics where he led Trodelvy development, and independent director Roy Baynes, MD PhD, the former Chief Medical Officer of Merck (MSD) and architect of the Keytruda development strategy.

Short descriptiontext

Adcendo ApS is a clinical-stage Danish biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need, including soft tissue sarcoma and solid tumors. Pre-revenue, the company has raised $453 million across multiple financing rounds.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFrederiksberg, Denmark
HQ citystring
Frederiksberg
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody drug conjugates, oncology therapeutics, targeted cancer therapy, clinical-stage biotech, biopharmaceutical development
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Antibody-Drug Conjugates
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotechnology company developing ADC pipeline for cancer treatment. Revenue will be generated through eventual product sales following regulatory approval. Pipeline includes ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), and ADCE-B05 (undisclosed target). Company also receives milestone payments and royalties from licensing agreements.

adcendo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Adcendo is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The pipeline comprises three clinical-stage ADC candidates (ADCE-T02, ADCE-D01, ADCE-B05) targeting novel cancer antigens including Tissue Factor (TF), uPARAP and an undisclosed target, plus a discovery-stage asset (A0401) developed using the company's proprietary A0401 drug discovery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • FDA Fast Track Designation granted to ADCE-D01 for treatment of soft tissue sarcoma (October 2025)
+3 more records
Product overview1 text field

Adcendo is a clinical-stage biotechnology company developing a pipeline of first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need. The company's portfolio consists of three clinical-stage ADC candidates: ADCE-T02 (Tissue Factor targeting, Phase I), ADCE-D01 (uPARAP targeting, Phase I/II), and ADCE-B05 (undisclosed target, Phase I), plus a discovery-stage asset A0401. The company integrates novel targets with optimized linker-payload combinations including topoisomerase I inhibitor payloads (exatecan-based T1000 and P1021).

Product and service4 records
1ADCE-T02
CategoryAntibody-Drug Conjugates
Description

A clinical-stage antibody-drug conjugate targeting Tissue Factor (TF), a target validated through the Adcendo innovation fund program with University of Copenhagen and Rigshospitalet; intended for treatment of solid tumors.

2ADCE-D01
3ADCE-B05
4A0401
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Clinical trial collaboration and supply agreement with MSD to evaluate ADCE-T02 in combination with KEYTRUDA (pembrolizumab) in a Phase Ib study in patients with advanced solid tumors. Adcendo sponsors the Phase 1b clinical trial and MSD provides pembrolizumab. Each party retains commercial rights to their respective compounds.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-20
Description

Global development and commercialization agreement for ADCE-T02 (Tissue Factor targeting ADC). Adcendo obtains exclusive development and commercialization rights globally except Greater China region where Multitude retains rights. Multitude would receive upfront and milestone payments over $1 billion plus single-digit to low double-digit tiered royalties on future product sales.

3Duality Biologics
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-05
Description

License agreement for DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for lead uPARAP-ADC program. DITAC platform designed to generate ADCs with superior safety profiles, sustainable payload delivery and release in tumors, and efficient bystander killing.

adcendo.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC developer with multiple proprietary platforms (Dolasynthen, Immunosynthen) advancing assets in solid tumors. Closely comparable to Adcendo in stage, modality and oncology focus.

TypeDirect peer
Description

Commercial and clinical-stage ADC company with approved product Zynlonta and a pipeline of pyrrolobenzodiazepine-based ADCs. Direct peer in ADC modality with comparable oncology focus.

TypeDirect peer
Description

Clinical-stage ADC developer leveraging novel tumor-microenvironment targets. Direct peer in modality and oncology indication overlap with Adcendo.

TypeDirect peer
Description

Clinical-stage ADC company developing next-generation ADCs with proprietary linker-payload technology. Direct peer recently acquired by Genmab, validating ADC platform M&A thesis applicable to Adcendo.

5Duality Biologics
TypeDirect peer
Description

ADC platform licensor to Adcendo (DITAC) and developer of its own pipeline of next-generation ADCs. Direct peer in modality and a key platform counterparty for Adcendo's lead program.

TypeDirect peer
Description

Clinical-stage ADC biotech with proprietary payload and conjugation platforms. Direct peer in ADC modality and pipeline stage with comparable oncology focus.

TypeDirect peer
Description

Clinical-stage ADC developer using proprietary Amanitin payload platform. Direct peer in ADC modality with comparable pipeline stage and oncology focus.

8Mythic Therapeutics
TypeDirect peer
Description

Clinical-stage ADC biotech developing ADCs against novel oncology targets. Direct peer in modality and development stage, recently acquired by GSK, illustrating the ADC-platform M&A precedent.

TypeDirect peer
Description

ADC biotech and Adcendo's licensing partner on the ADCE-T02 Tissue Factor program. Direct peer in modality with overlapping pipeline in TF-targeting oncology indications.

TypeBroad incumbent
Description

Large global pharmaceutical company that pioneered Enhertu and Datroway ADCs in partnership with AstraZeneca. Broad incumbent in the ADC category and a benchmark for what scale a successful ADC franchise can achieve.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

abcendo

Antibody-Drug Conjugatesadcendo.com

Adcendo ApS is a clinical-stage Danish biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need, including soft tissue sarcoma and solid tumors. Pre-revenue, the company has raised $453 million across multiple financing rounds.

What abcendo does

Adcendo ApS is a clinical-stage biotechnology company founded in 2017 as a spin-out from the University of Copenhagen and Rigshospitalet, headquartered in Copenhagen, Denmark, with US operations established through Adcendo U.S. Inc. in Boston, Massachusetts in April 2025. The company develops a portfolio of first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need, integrating novel target biology with optimized linker-payload combinations. Adcendo's pipeline consists of three clinical-stage ADC candidates: ADCE-T02, a potential best-in-class Tissue Factor-targeting ADC using a next-generation exatecan-based T1000 linker-payload for solid tumors including HNSCC, PDAC, CRC, NSCLC, and cervical cancer; ADCE-D01, a first-in-class ADC targeting uPARAP (urokinase plasminogen activator receptor-associated protein) conjugated to the P1021 topoisomerase I inhibitor payload for mesenchymal cancers including soft tissue sarcoma, and granted FDA Fast Track and Orphan Drug Designation; and ADCE-B05, a first-in-class ADC against an undisclosed target in squamous cell carcinomas. The company also holds a preclinical discovery asset (A0401) and has licensed the DITAC linker/payload platform from Duality Biologics.

As a pre-revenue clinical-stage company, Adcendo generates no product sales today. Its economic model is structured around licensing, milestone, and royalty agreements with pharmaceutical partners. The principal commercial agreement is a global development and commercialization deal with Multitude Therapeutics for ADCE-T02 (excluding Greater China), which could deliver over $1 billion in upfront and milestone payments plus single-digit to low double-digit tiered royalties. A clinical collaboration with MSD will evaluate ADCE-T02 in combination with KEYTRUDA (pembrolizumab) in a Phase Ib study. Future revenue will ultimately derive from product commercialization through specialty oncology channels following regulatory approval, complemented by licensing income.

The company has raised approximately $453 million across multiple financing rounds including a EUR 98 million Series A (with extensions in 2021, 2023, and 2024), a $135 million Series B in November 2024 led by TCGX, and a $75 million Series C in April 2026 led by Jeito Capital. The investor base comprises a syndicate of healthcare specialist funds including TCGX, Jeito Capital, Novo Holdings, RA Capital, TPG, Orbimed, Pontifax, Ysios, HealthCap, Gilde Healthcare, Venrock, Surveyor Capital (Citadel), Logos Capital, Vida Ventures, BPI France, EIFO, and Dawn Biopharma (KKR platform). Leadership includes CEO Michael Pehl, formerly of Celgene and Immunomedics where he led Trodelvy development, and independent director Roy Baynes, MD PhD, the former Chief Medical Officer of Merck (MSD) and architect of the Keytruda development strategy.

abcendo firmographics

Firmographics
Name
abcendo
Legal name
Adcendo ApS
Website
https://adcendo.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Adcendo ApS is a clinical-stage Danish biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need, including soft tissue sarcoma and solid tumors. Pre-revenue, the company has raised $453 million across multiple financing rounds.
Ownership category
akta.pro rank

abcendo industry classification

Industry
Product category
Antibody-Drug Conjugates
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody drug conjugates
  • Oncology therapeutics
  • Targeted cancer therapy
  • Clinical-stage biotech
  • Biopharmaceutical development

Where abcendo is headquartered

Location

Headquarters

HQ city
Frederiksberg
HQ country
Denmark
HQ region
Europe

Offices2 records

Markets served

abcendo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing ADC pipeline for cancer treatment. Revenue will be generated through eventual product sales following regulatory approval. Pipeline includes ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), and ADCE-B05 (undisclosed target). Company also receives milestone payments and royalties from licensing agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

abcendo product offering

Product offering

Core offering

Adcendo is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The pipeline comprises three clinical-stage ADC candidates (ADCE-T02, ADCE-D01, ADCE-B05) targeting novel cancer antigens including Tissue Factor (TF), uPARAP and an undisclosed target, plus a discovery-stage asset (A0401) developed using the company's proprietary A0401 drug discovery platform.

Product overview

Adcendo is a clinical-stage biotechnology company developing a pipeline of first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need. The company's portfolio consists of three clinical-stage ADC candidates: ADCE-T02 (Tissue Factor targeting, Phase I), ADCE-D01 (uPARAP targeting, Phase I/II), and ADCE-B05 (undisclosed target, Phase I), plus a discovery-stage asset A0401. The company integrates novel targets with optimized linker-payload combinations including topoisomerase I inhibitor payloads (exatecan-based T1000 and P1021).

Differentiator

Problem solved

Functional benefit

Products and services

  • ADCE-T02 A clinical-stage antibody-drug conjugate targeting Tissue Factor (TF), a target validated through the Adcendo innovation fund program with University of Copenhagen and Rigshospitalet; intended for treatment of solid tumors.
  • ADCE-D01
  • ADCE-B05
  • A0401

Quantifiable outcome

  • FDA Fast Track Designation granted to ADCE-D01 for treatment of soft tissue sarcoma (October 2025)
  • +3 more outcomes

Companies that use abcendo

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

abcendo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

abcendo partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • MSD (Merck & Co., Inc.)coreStrategic or Co-development Partner · 26 May 2026Clinical trial collaboration and supply agreement with MSD to evaluate ADCE-T02 in combination with KEYTRUDA (pembrolizumab) in a Phase Ib study in patients with advanced solid tumors. Adcendo sponsors the Phase 1b clinical trial and MSD provides pembrolizumab. Each party retains commercial rights to their respective compounds.
  • Multitude Therapeutics Inc.coreStrategic or Co-development Partner · 20 August 2024Global development and commercialization agreement for ADCE-T02 (Tissue Factor targeting ADC). Adcendo obtains exclusive development and commercialization rights globally except Greater China region where Multitude retains rights. Multitude would receive upfront and milestone payments over $1 billion plus single-digit to low double-digit tiered royalties on future product sales.
  • Duality BiologicscoreTechnology or Integration · 5 January 2023License agreement for DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for lead uPARAP-ADC program. DITAC platform designed to generate ADCs with superior safety profiles, sustainable payload delivery and release in tumors, and efficient bystander killing.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

abcendo competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Clinical-stage ADC developer with multiple proprietary platforms (Dolasynthen, Immunosynthen) advancing assets in solid tumors. Closely comparable to Adcendo in stage, modality and oncology focus.
  • ADC Therapeutics: Commercial and clinical-stage ADC company with approved product Zynlonta and a pipeline of pyrrolobenzodiazepine-based ADCs. Direct peer in ADC modality with comparable oncology focus.
  • Pyxis Oncology: Clinical-stage ADC developer leveraging novel tumor-microenvironment targets. Direct peer in modality and oncology indication overlap with Adcendo.
  • ProfoundBio: Clinical-stage ADC company developing next-generation ADCs with proprietary linker-payload technology. Direct peer recently acquired by Genmab, validating ADC platform M&A thesis applicable to Adcendo.
  • Duality Biologics: ADC platform licensor to Adcendo (DITAC) and developer of its own pipeline of next-generation ADCs. Direct peer in modality and a key platform counterparty for Adcendo's lead program.
  • Tubulis: Clinical-stage ADC biotech with proprietary payload and conjugation platforms. Direct peer in ADC modality and pipeline stage with comparable oncology focus.
  • Heidelberg Pharma: Clinical-stage ADC developer using proprietary Amanitin payload platform. Direct peer in ADC modality with comparable pipeline stage and oncology focus.
  • Mythic Therapeutics: Clinical-stage ADC biotech developing ADCs against novel oncology targets. Direct peer in modality and development stage, recently acquired by GSK, illustrating the ADC-platform M&A precedent.
  • Multitude Therapeutics: ADC biotech and Adcendo's licensing partner on the ADCE-T02 Tissue Factor program. Direct peer in modality with overlapping pipeline in TF-targeting oncology indications.

Broad incumbents

  • Daiichi Sankyo: Large global pharmaceutical company that pioneered Enhertu and Datroway ADCs in partnership with AstraZeneca. Broad incumbent in the ADC category and a benchmark for what scale a successful ADC franchise can achieve.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

abcendo social profiles

Digital presence

abcendo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

abcendo leadership team

Management profile

Number of profiles

Profiles9 records

abcendo subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

abcendo funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

abcendo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about abcendo

What does abcendo do?

Adcendo is a clinical-stage biotechnology company developing a pipeline of next-generation antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The pipeline comprises three clinical-stage ADC candidates (ADCE-T02, ADCE-D01, ADCE-B05) targeting novel cancer antigens including Tissue Factor (TF), uPARAP and an undisclosed target, plus a discovery-stage asset (A0401) developed using the company's proprietary A0401 drug discovery platform.

Is abcendo a public or private company?

abcendo is a private company. It is classified as venture growth investor backed and is currently operating.

When was abcendo founded?

abcendo was founded in 2017. It employs 11 to 50 people.

Where is abcendo based?

abcendo is headquartered in Frederiksberg, Denmark, in the Europe region.

How does abcendo make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are abcendo's main competitors?

Direct peers on record are Mersana Therapeutics, ADC Therapeutics, Pyxis Oncology, ProfoundBio, Duality Biologics, Tubulis, Heidelberg Pharma, Mythic Therapeutics and Multitude Therapeutics. Daiichi Sankyo is listed as a broad incumbent.

Does abcendo have an API?

No public API is recorded for abcendo.

What industry is abcendo in?

abcendo's product category is Antibody-Drug Conjugates. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAdcendo ApS to Present ADCE-D01 Phase 1 Clinical Data in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsAdcendo will present initial clinical data from the Phase 1 ADCElerate1 trial of ADCE-D01, an ADC targeting uPARAP, in advanced soft tissue sarcoma at the 2026 EORTC-NCI-AACR Symposium. The presentation is scheduled for November 19, 2026, in Barcelona, Spain.PR NewswireAdcendo ApS to Present ADCE-D01 Phase 1 Clinical Data in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsAdcendo will present initial clinical data from the Phase 1 ADCElerate1 trial of ADCE-D01, an ADC targeting uPARAP, in advanced soft tissue sarcoma at the 2026 EORTC-NCI-AACR Symposium. The presentation is scheduled for November 19, 2026, in Barcelona, Spain.NewswireAdcendo ApS to Present ADCE-D01 Phase 1 Clinical Data in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsAdcendo will present initial clinical data from the Phase 1 ADCElerate1 trial of ADCE-D01, an ADC targeting uPARAP, in advanced soft tissue sarcoma at the 2026 EORTC-NCI-AACR Symposium. The oral presentation, led by Dr. Patrick Schöffski, will be held on November 19, 2026, in Barcelona.Clinical Trials ArenaMSD and Adcendo sign collaboration agreement for Phase Ib trialMSD and Adcendo signed a collaboration and supply agreement to evaluate ADCE-T02 with Keytruda in a Phase Ib trial for advanced solid tumour patients. Adcendo will sponsor the trial, MSD will provide pembrolizumab, and both companies retain commercial rights. The first patient is expected to be dosed in the second half of 2026.European BiotechnologyAdcendo inks MSD supply deal to run ADC-Keytruda combination studyAdcendo plans to start a Phase Ib trial in the second half of the year combining its TF-directed ADC ADCE-T02 with MSD's Keytruda. The trial aims to test safety and tolerability, potentially improving on Tivdak's adverse events. The company will test escalating doses of ADCE-T02 with the standard Keytruda dose.NewswireAdcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug ConjugatesAdcendo announced updates on its ADC pipeline, including ADCE-T02 entering cohort expansion in the Tiffany-01 trial, ADCE-D01 receiving FDA Orphan Drug Designation for soft tissue sarcoma, and first patient dosing in the ADCE-B05 Phase I trial. The company plans to accelerate clinical programs with proceeds from its Series C financing.WebcapitalriesgoYsios Capital participa en la ronda Serie C de $75M de AdcendoYsios Capital participated in Adcendo's $75 million Series C round, led by Jeito Capital, with new investors including Vida Ventures, Bpifrance, and EIFO. The funding will support development of three ADC programs, including ADCE-T02, ADCE-D01, and ADCE-B05. Ysios Capital, which led the Series A in 2021, reaffirmed its confidence in the company.VenturecapitalAdcendo Secures $75M in Series C Funding for Cancer Treatment AdvancementAdcendo closed a $75 million Series C financing round led by Jeito Capital to advance antibody-drug conjugates for high unmet medical need cancers. The funding supports the company's clinical development strategy.The Pharma LetterAdcendo completes $75 million Series C financingAdcendo closed an oversubscribed $75 million Series C financing round. The proceeds will fund multiple clinical trials, including the ADCE-T02 Phase I expansion, ADCE-D01 dose escalation, and ADCE-B05 dose escalation studies.InvestorsinhealthcareDenmark: Adcendo completes US$75m Series C financing roundAdcendo, a Denmark-based biotech company developing antibody-drug conjugates for cancers with high unmet medical need, closed an oversubscribed US$75m Series C financing round. The company focuses on first-and best-in-class ADCs for such indications.